Furiex (FURX) Says PPD-10558 Did Not Meet Primary Efficacy Endpoint in Phase II Trial
Tweet
Share
E-mailGet Alerts FURX Hot Sheet
Join SI Premium – FREE
Furiex (Nasdaq: FURX) said results for Phase II trial of PPD-10558 did not meet the primary efficacy endpoint.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
